Personalized use of irinotecan in colorectal cancer patients based on real world studies and pharmacogenomics
Ontology highlight
ABSTRACT: Interventions: Wild-type group:None;Single heterozygous group:None;Mutant homozygous/double heterozygous group:None
Primary outcome(s): Efficacy;The incidence of adverse events
Study Design: Cohort study
DISEASE(S): Colorectal Cancer
PROVIDER: 89703 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA